JBIO — Jade Biosciences, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-06-30.
Performance
Technicals
Others in Healthcare
Measured signals that fired on JBIO
| date | signal | measured base rate |
|---|---|---|
| 2026-08-13 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-08-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-23 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-18 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-06-02 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-21 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-02-12 | Dahms Bradford D. Chief Financial Officer | Grant or award | 37.8K | 0.00 | 0 |
| 2026-02-12 | Frohlich Tom Chief Executive Officer | Grant or award | 78.8K | 0.00 | 0 |
| 2026-02-12 | King Andrew James See Remarks | Grant or award | 41.2K | 0.00 | 0 |
| 2026-02-12 | Balta Elizabeth See Remarks | Grant or award | 28.1K | 0.00 | 0 |
| 2025-10-06 | Fairmount Healthcare Fund II L.P. Director | Grant or award | 1.3M | 9.14 | 12.2M |
| 2025-10-06 | Fairmount Funds Management LLC Director | Grant or award | 1.3M | 9.14 | 12.2M |
| 2025-10-06 | Kiselak Tomas Director | Grant or award | 1.3M | 9.14 | 12.2M |
| 2025-10-06 | Fairmount Healthcare Co-Invest IV L.P. Director | Grant or award | 1.3M | 9.14 | 12.2M |
| 2025-10-06 | Harwin Peter Evan Director | Grant or award | 1.3M | 9.14 | 12.2M |
| 2025-05-16 | Frohlich Tom Chief Executive Officer | Open-market purchase | 6.0K | 7.40 | 44.4K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| FMR LLC | 99.6M | 7.1M |
| Fairmount Funds Management LLC | 64.0M | 4.6M |
| Avidity Partners Management LP | 53.9M | 2.8M |
| RA CAPITAL MANAGEMENT, L.P. | 51.6M | 3.7M |
| Bellevue Group AG | 49.2M | 3.5M |
| Venrock Adviser, LLC | 45.2M | 3.2M |
| JANUS HENDERSON GROUP PLC | 43.6M | 3.1M |
| BlackRock, Inc. | 32.5M | 2.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | 25.2M | 1.8M |
| BAKER BROS. ADVISORS LP | 23.1M | 1.6M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about JBIO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →